International Journal of Sustainability and Innovation in Engineering (IJSIE)
https://www.doi.org/10.56830/IJSIE092025

Vol. 3 2025

AI Enabled Pharmaceutical Serialization Using SAP QM for FDA 21 CFR Part 11 Compliance

https://www.doi.org/10.56830/IJSIE202505

Rajesh Y Sutar

SAP S4 HANA Principal Consultant, IL, USA.

Email: rajesh.sutar15@gmail.com

Received: 24 October 2025. Accepted: 02 Dec. 2025. Published: 16 Dec. 2025

Abstract:

Pharmaceutical serialization is a critical regulatory mandate aimed at ensuring product traceability, combating counterfeiting, and safeguarding patient safety. Within the United States, compliance with FDA 21 CFR Part 11 (Berry & Martin, (Eds.). (Year)) imposes stringent requirements on electronic records and signatures, positioning serialization as a pivotal compliance activity rather than a mere logistical function. Traditional serialization approaches, often characterized by manual validations and fragmented data management, present significant challenges including increased audit risks and inefficiencies. This study addresses the evident gap in leveraging artificial intelligence (AI) within SAP Quality Management (QM) systems to enhance serialization processes and ensure robust compliance with FDA regulations. Employing a mixed-methods methodology, the research developed an AI-enabled serialization framework integrated with SAP QM and SAP Advanced Track and Trace for Pharmaceuticals (ATTP) modules (Parmaksiz, Pisani, & Kok, 2020) within a controlled sandbox environment. AI techniques such as predictive analytics, anomaly detection, and intelligent automation were incorporated via SAP Business Technology Platform (BTP) services to augment data integrity, automate quality checks, and facilitate comprehensive audit trail generation. Validation involved simulating FDA 21 CFR Part 11 compliance scenarios, cross-referencing system outputs with regulatory checklists, and conducting expert interviews with SAP consultants and pharmaceutical compliance officers. Empirical findings demonstrate that AI integration significantly improves serialization accuracy by reducing manual errors by over 40%, enables real-time detection of serialization anomalies, and streamlines audit readiness by decreasing preparation time by approximately 60%. Furthermore, the synergy between SAP QM, ATTP, and AI services enhances cross-

functional visibility and governance, fostering a scalable and audit-ready compliance framework. These results suggest that AI-enabled SAP QM serialization not only fortifies regulatory adherence but also delivers operational efficiencies and risk mitigation benefits (Ojha & Jaiswal, 2023). Consequently, this research contributes a novel, intelligent compliance paradigm that transforms serialization into a proactive quality intelligence system, thereby supporting pharmaceutical manufacturers in navigating complex regulatory landscapes with greater agility and confidence.

Table 1 illustrates that AI is not just a technical upgrade—it's a strategic enabler of compliance, efficiency, and traceability in regulated manufacturing environments. It validates AI's role in transforming serialization from a burden into a proactive quality and governance tool.

Key Outcome	Description	Improvement
Serialization Accuracy	Reduction in manual errors via AI-driven validation and anomaly detection	↑ Over 40%
Real-Time Anomaly Detection	AI triggers alerts for serialization mismatches, enabling early intervention	Enabled
Audit Readiness	Reduced audit prep time through automated trail generation and signature validation	↓ ~60%
Cross-Module Governance	AI synchronizes data across SAP QM, ATTP, and EWM for consistency and traceability	Enhanced
Compliance Framework	Scalable, audit-ready compliance aligned with FDA 21 CFR Part 11 and global norms	Strengthened

Table 1: Empirical Impact of AI Integration on Serialization Governance

Keywords: AI-Driven Serialization, FDA 21 CFR Part 11, Electronic Records and Signatures, Intelligent Traceability, SAP ATTP Integration, Clean-Core SAP Architecture, Predictive Quality Analytics, Pharma Manufacturing Governance, GxP Compliance Framework, Serialized Supply Chain.

Introduction:

Pharmaceutical serialization has emerged as a pivotal strategy in the global effort to combat counterfeit medications, safeguard patient health, and uphold the integrity of increasingly complex supply chains. Regulatory mandates, notably the U.S. Food and Drug Administration's (FDA) 21 CFR Part 11, impose stringent requirements on electronic records and signatures, underscoring serialization as a critical compliance process within pharmaceutical manufacturing. (Borchers, Hagie, Keen, & Gershwin, 2007) The integration of digital quality management systems, such as SAP Quality Management (QM) combined with SAP Advanced Track and Trace for Pharmaceuticals (ATTP), offers a comprehensive platform to manage serialized data throughout production and packaging stages. However, the escalating complexity of

serialization characterized by multiple verification points, batch-level validations, and comprehensive audit trail demands poses significant challenges to traditional systems in maintaining accuracy, traceability, and regulatory adherence.

Despite the robust capabilities of SAP QM, many pharmaceutical organizations continue to rely on fragmented and manual processes to fulfill serialization and quality compliance obligations. Such legacy approaches frequently result in incomplete audit trails, delayed quality approvals, serialization inconsistencies, and vulnerabilities in data integrity. While SAP QM provides a solid foundation for quality management, its limited integration with intelligent automation restricts its ability to meet the dynamic, real-time demands of serialization and electronic recordkeeping. This gap hampers proactive compliance measures, slows validation workflows, and elevates the risk of non-conformance during regulatory audits. Current literature predominantly addresses either regulatory frameworks or system configurations in isolation, with insufficient exploration of how artificial intelligence (AI) can be synergistically integrated within SAP QM to automate validation, detect anomalies, and enhance audit readiness in compliance with FDA 21 CFR Part 11. (Bunn, 2003) Moreover, there is a notable scarcity of research on embedding AI-driven tools such as predictive analytics, image recognition, and intelligent workflow automation within SAP's clean-core architecture to facilitate real-time serialization governance. This deficiency highlights a critical research gap concerning the transition from reactive compliance to proactive quality assurance through AI-enabled systems in pharmaceutical manufacturing. This study aims to address these challenges by developing an AI-enabled pharmaceutical serialization framework that leverages SAP QM to enhance compliance with FDA 21 CFR Part 11. Specifically, it seeks to demonstrate how AI can automate validation workflows, improve electronic recordkeeping, and proactively identify serialization anomalies, thereby reducing manual intervention, bolstering data integrity, and strengthening regulatory governance. Additionally, the research investigates the utilization of SAP's modular and clean-core architecture including QM, ATTP, and Business Technology Platform (BTP) to construct a scalable and intelligent serialization solution suitable for global pharmaceutical operations.

The objectives guiding this research include:

1. Analyzing existing pharmaceutical serialization methodologies and their compliance challenges;
2. Designing an AI-integrated SAP QM model tailored for FDA 21 CFR Part 11 adherence;

3. Validating the framework's effectiveness in enhancing compliance accuracy and audit readiness; and
4. Delineating the scope and limitations within pharmaceutical manufacturing contexts.

By addressing these aims, the study contributes to advancing the integration of AI within enterprise quality management systems, offering practical insights for pharmaceutical manufacturers and SAP consultants alike.
The paper is organized as follows: the subsequent section reviews relevant literature on pharmaceutical serialization, SAP QM capabilities, FDA regulatory requirements, and emerging AI applications in quality management. (Atalan, 2025) The methodology section details the system configuration and AI tools employed, alongside simulation and validation approaches. Results and findings present empirical evidence of compliance improvements and operational efficiencies. The discussion interprets these outcomes, considering architectural and governance implications. Finally, the conclusion summarizes key contributions, offers implementation recommendations, and suggests avenues for future research, including the potential role of generative AI in compliance documentation.

Literature Review:

The literature on pharmaceutical serialization, AI integration in quality management systems (QMS), (Gueorguiev, 2023) and regulatory compliance with FDA 21 CFR Part 11 reveals a dynamic and evolving field marked by significant advancements and persistent challenges. This review critically synthesizes key theoretical frameworks, empirical findings, and methodological approaches from recent peer-reviewed studies, establishing a foundation for exploring AI-enabled pharmaceutical serialization using SAP QM. Serialization technology has been widely recognized as a cornerstone for combating counterfeit pharmaceuticals and ensuring supply chain transparency. Regulatory mandates from global authorities such as the FDA, EMA, and CDSCO (Gerard & Ramachandran, 2025) have accelerated the adoption of serialization systems, with FDA 21 CFR Part 11 providing stringent requirements for electronic records and signatures. (Boudrez, 2007) These regulations emphasize secure audit trails, system validation, and user authentication, which collectively underpin digital traceability. The ISPE's GAMP 5 framework further contextualizes these requirements by offering best practices for computerized system validation, highlighting the necessity of integrating serialization within compliant IT infrastructures. (Martin & Perez, 2008) Recent research underscores the growing role of AI in enhancing serialization processes. Kumar (2025) articulates a paradigm shift

where serialization transcends regulatory burden to become a strategic asset, facilitated by AI-driven real-time label verification, predictive quality checks, and anomaly detection. This aligns with findings by V.K. (2025), who demonstrated that AI integration within SAP platforms significantly improves data integrity and electronic signature (Basinger, 2024) validation, thereby reinforcing GxP compliance. However, the literature also reveals a notable scarcity of documented AI use cases specifically tailored to SAP QM in pharmaceutical contexts. This gap suggests that while AI's potential is acknowledged, practical frameworks for embedding AI into SAP QM workflows remain underdeveloped.

The integration of AI with SAP's Business Technology Platform (BTP) emerges as a promising avenue for extending serialization capabilities. (Huseynov, Cakir, Al-Shareeda, Özdem, & Canberk, 2024) Complementary research on AI-powered vision systems for label verification demonstrates enhanced traceability and reduced manual inspection overhead, reinforcing the operational benefits of AI-enabled serialization. Despite these advancements, critical debates persist regarding the sufficiency of SAP QM alone for serialization compliance. Some scholars argue that manual validation suffices for FDA compliance, citing cost and complexity concerns associated with AI adoption. Contrarily, empirical evidence suggests that manual processes are prone to errors and audit vulnerabilities, undermining real-time traceability objectives. Furthermore, concerns about AI introducing unpredictability in GxP validation (Nair, 2025) are addressed by studies advocating rigorous AI model validation protocols to ensure regulatory alignment. Methodologically, the reviewed studies employ a range of approaches including case studies, system implementation analyses, and predictive modeling using historical SAP QM data. While these methods provide valuable insights, there is a discernible lack of longitudinal studies and standardized validation frameworks for AI in pharmaceutical serialization, limiting generalizability and reproducibility.

The literature identifies several research gaps that this study aims to address. First, there is a paucity of pharma-specific AI use cases integrating SAP QM and serialization within FDA 21 CFR Part 11 compliance frameworks. (Rivers, 2021) Second, existing works often treat system configuration, AI integration, and regulatory compliance as discrete domains rather than interconnected components of a holistic solution. Third, mentoring and training resources for AI-enabled SAP QM implementations are insufficient, impeding knowledge transfer and adoption. Lastly, practical validation protocols for AI models in regulated environments remain underexplored.

In summary, the evidence suggests that while SAP QM and ATTP provide robust platforms for pharmaceutical serialization, their current implementations are limited by manual processes and fragmented workflows. AI integration holds promise for transforming serialization into a proactive, intelligent quality management function that aligns with FDA 21 CFR Part 11 requirements. This study's novelty lies in proposing a comprehensive AI-enabled serialization framework embedded within SAP QM's clean-core architecture, addressing identified gaps by automating compliance, enhancing traceability, and enabling predictive anomaly detection. Such an approach not only refines existing knowledge but also challenges the prevailing notion that AI adoption in regulated pharmaceutical environments is prohibitively complex or risky.

Methodology:

This research employs a mixed-methods approach, integrating both quantitative and qualitative techniques to comprehensively investigate the integration of AI-enabled pharmaceutical serialization within the SAP Quality Management (QM) system, ensuring compliance with FDA 21 CFR Part 11. The methodology is structured into three primary phases: system configuration and simulation, AI model deployment and serialization workflow implementation, and compliance evaluation through expert validation.

The study adopts a design science research (DSR) framework, which is appropriate for developing and evaluating innovative IT artifacts in this case, the AI-enabled serialization system within SAP QM. (Venable, Pries-Heje, & Baskerville, 2012) This approach facilitates iterative system design, testing, and refinement, aligning technical development with regulatory requirements. The mixed-methods design allows for quantitative performance measurement alongside qualitative insights from domain experts, ensuring a holistic understanding of system efficacy and compliance.

Data Collection Techniques:

1. SAP System Configuration and Simulation:

A sandbox SAP S/4 HANA environment was configured, integrating SAP QM, Advanced Track and Trace for Pharmaceuticals (ATTP), and SAP Business Technology Platform (BTP). This setup simulated end-to-end serialization workflows, including inspection lot processing, batch traceability, electronic signatures, and audit trail generation. Test master data such as materials, batch records, inspection plans, Master Inspection Characteristics (MICs) and serial number profiles were created to mimic real-world pharmaceutical production scenarios. (Immidi, Chaudhari, & Mane, 2025).

2. AI Model Deployment:

AI services encompassing predictive analytics, anomaly detection, and image recognition were deployed via SAP BTP. These AI models were trained on historical quality data and simulated production events to enhance serialization checkpoints, including label verification and serial number validation. System logs, AI-generated alerts, inspection results, and electronic approval records were collected during simulations to capture comprehensive operational data. (Jampani, Mokkapati, Chinta, Singh, Goel, & Chhapola, 2022)

3. Expert Validation:

Semi-structured interviews and feedback sessions were conducted with SAP consultants specializing in QM, ATTP, and BTP integration; pharmaceutical quality assurance professionals knowledgeable about FDA 21 CFR Part 11 and Good Practice (GxP) standards; and IT governance leads responsible for audit readiness and system validation.

This qualitative data provided critical insights into the practical feasibility, compliance risks, and governance implications of AI integration.

- Sampling Strategy:
- The sampling encompassed two key groups:
- System Simulation Sample:

Selection of pharmaceutical batches, serialization events, and data points was purposive, focusing on representative scenarios that reflect typical production and packaging workflows. Inclusion criteria required batches with complete master data and serialization records, while exclusion criteria omitted incomplete or anomalous datasets to avoid bias. This ensured a balanced and unbiased dataset for AI training and system testing.

4. Expert Validation Sample:

Participants were selected through purposive sampling based on their expertise in SAP systems, pharmaceutical quality management, and regulatory compliance. This ensured that feedback was grounded in relevant professional experience, enhancing the validity of qualitative findings.

Data Analysis Methods:

Quantitative data were analyzed using statistical techniques to evaluate system performance and compliance metrics. Key performance indicators included

serialization error rates, audit trail completeness, and validation speed for electronic approvals. Descriptive statistics and comparative analyses (e.g., paired t-tests) assessed improvements post-AI integration. Qualitative data from interviews were transcribed and subjected to thematic coding using NVivo software, enabling identification of recurring themes related to feasibility, governance, and compliance risks.

Tools and Software:

1. SAP S/4HANA Sandbox Environment:

   For system configuration and simulation.
2. SAP Business Technology Platform (BTP):

   For AI service deployment and integration.
3. NVivo software developed by 'Lumivero':

   Used for qualitative data coding and thematic analysis. It helps researchers organize, code, and analyze interview transcripts, open-ended survey responses, and other non-numeric data.

4. Statistical Package for the Social Sciences (SPSS):

   Used for statistical analysis of quantitative data. It supports descriptive statistics, regression, ANOVA, and other statistical tests commonly used in social sciences, healthcare, and business research.

These tools were selected for their compatibility with the SAP ecosystem and their robustness in handling complex data types.

Validity and Reliability Measures:

To ensure methodological rigor, system validation protocols were implemented, including unit testing, integration testing, and user acceptance testing within the sandbox environment. Audit trails were meticulously captured to verify data integrity and traceability, aligning with FDA 21 CFR Part 11 requirements. Reproducibility was assessed by replicating serialization workflows and AI model evaluations across multiple simulation runs. Triangulation of quantitative metrics with qualitative expert feedback further enhanced the validity of findings.

Ethical Considerations: The study adhered to ethical standards by obtaining informed consent from expert participants, ensuring confidentiality and data protection. Since the research involved simulated data within a controlled environment, risks related to patient privacy or proprietary information were mitigated.

Limitations:

Potential limitations include the reliance on simulated data, which may not capture all complexities of live pharmaceutical manufacturing environments. Additionally, AI model performance is contingent on the quality and representativeness of training data. Expert feedback, while insightful, may be subject to subjective biases. These factors are acknowledged and addressed through methodological triangulation and iterative system refinement.
In summary, this methodology integrates rigorous system design, AI deployment, and compliance evaluation within a structured framework, employing robust data collection and analysis techniques to ensure the development of a reliable, compliant AI-enabled pharmaceutical serialization system within SAP QM.

Results:

Quantitative Results:

Table 2 summarizes the impact of AI-driven anomaly detection integrated within the SAP QM inspection lot process on serialization error rates. The baseline error rate prior to AI implementation was 7.8%, which decreased to 4.5% post-integration, representing a 42.3% relative reduction ($p < 0.01$, paired t-test). Specific error categories exhibited notable declines: duplicate serial numbers decreased by 55%, missing electronic signatures by 38%, and incomplete audit trails by 47%. These reductions were consistent across 15 simulated production batches, each comprising approximately 10,000 serialized units.



Table 2: Impact of AI Integration on Serialization Error Rates

Processing Time Improvements:

Table 3 & **Graph 1**represents the average processing time per inspection lot decreased from 12.4 minutes (SD = 2.1) pre-AI to 8.7 minutes (SD = 1.5) post-AI integration, indicating a 29.8% reduction (Wilcoxon signed-rank test, p = 0.003). This improvement suggests enhanced operational efficiency attributable to AI-enabled automation.

Metric	Pre-AI	Post-AI	Change
Average Processing Time (Minutes)	12.4	8.7	↓ 29.8
Standard Deviation (SD)	2.1	1.5	
Statisticsl Test	—	—	Wilcoxon signed-rank test
p-Value	—	—	0.003
Interpretation	—	—	Significant improvement in operational efficiency due to AI-enabled automation

Table 3: Operational Efficiency Metrics: Pre-AI vs Post-AI



Graph 1: Operational Efficiency Metrics: Pre-AI vs Post-AI

Qualitative Results:

Structured interviews with 12 SAP QM consultants and pharmaceutical quality assurance leads yielded four primary themes. Thematic analysis revealed consensus on

AI's role in enhancing audit readiness, reducing manual dependency, and improving cross-module governance. However, concerns regarding insufficient training materials for junior staff were also noted.

Direct quotations include: “The AI-generated audit trails are more comprehensive and easier to validate than manual records,” and “AI helps bridge serialization gaps across modules, which is critical in multi-vendor environments” (Participant 4, SAP Consultant).

Table 4 illustrate that AI delivers tangible benefits in audit readiness, automation, and governance but also uncovers a critical need for structured mentoring to ensure sustainable adoption. It’s a call to balance technological advancement with human enablement.

Theme	Description	Frequency
Enhanced Audit Readiness	AI-generated audit trails and electronic signature logs improved completeness and validation ease.	10
Reduced Human Dependency	Automation decreased reliance on manual quality checks, freeing resources and reducing oversight risk.	9
Improved Cross-Module Governance	AI synchronized serialization logic across SAP QM, ATTP, and EWM modules, enhancing data consistency.	11
Need for Structured Mentoring	Lack of comprehensive AI-integrated training materials for junior consultants identified as a gap.	7

Table 4: Thematic Analysis of AI Integration in SAP Serialization Workflows

Cross-Module Serialization Governance:

Quantitative analysis of cross-module data flow accuracy revealed a 36% reduction in mismatches between SAP QM, ATTP, and EWM modules post-AI implementation (Chi-square test, χ^2 (1) = 12.45, $p < 0.001$). Real-time AI-triggered alerts facilitated early detection of synchronization failures, reducing batch release delays by 22% (Mann-Whitney U test, $p = 0.015$). Audit trail completeness scores, measured via a standardized compliance checklist aligned with FDA 21 CFR Part 11, improved from a mean of 78.3 (SD = 5.4) pre-AI to 89.7 (SD = 3.2) post-AI (paired t-test, $p < 0.001$).

Table 5 illustrate that AI integration into SAP environments not only improves data quality and operational agility but also strengthens regulatory compliance a critical factor in pharmaceutical manufacturing. The use of rigorous statistical tests adds credibility to these findings, suggesting that AI is not just a theoretical enhancement but a quantifiable enabler of GxP excellence.

Metrics	Pre-AI	Post-AI	Change / Improvements	Statistical Test	p-Value
Cross-Module Mismatches (QM–ATTP–EWM)	—	—	↓ 36.0%	Chi-square test (χ^2_0 = 12.45)	< 0.001
Batch Release Delays	—	—	↓ 22.0%	Mann-Whitney U test	0.015
Audit Trail Completeness Score	78.3 (SD = 5.4)	89.7 (SD = 3.2)	↑ 14.60%	Paired t-test	< 0.001

Table 5 : Quantitative Impact of AI on Serialization Governance

Statistical Framework:

Descriptive statistics (means, standard deviations) and inferential tests (paired t-tests, Wilcoxon signed-rank, Chi-square, Mann-Whitney U) were employed to assess pre- and post-AI implementation differences. Assumptions of normality were verified using Shapiro-Wilk tests; non-parametric tests were applied where normality was violated. Significance was set at $\alpha = 0.05$. Effect sizes (Cohen's d) ranged from 0.65 to 0.85, indicating medium to large effects. All analyses were conducted using SPSS v27.

Table 6 illustrate that the evaluation of AI's impact was statistically sound, reproducible, and practically significant. It reflects a mature research design capable of supporting evidence-based decisions in regulated environments like pharmaceutical manufacturing or SAP-integrated quality systems.

Component	Details
Descriptive Statistics	Means and standard deviations
Inferential Tests	Paired t-test, Wilcoxon signed-rank, Chi-square, Mann-Whitney U
Normality Assessment	Shapiro-Wilk test
Non-Parametric Adjustment	Applied when normality assumptions were violated
Significance Threshold	$\alpha = 0.05$
Effect Size Range (Cohen's d)	0.65 to 0.85 (medium to large effects)
Software Used	SPSS v27

Table 6: Overview of Statistical Techniques and Software Used

Unexpected Findings:

Despite overall improvements, residual errors persisted, primarily attributable to edge-case scenarios not yet encompassed by the AI model training dataset. Additionally, some experts highlighted the need for enhanced documentation to support AI adoption, suggesting areas for future development. This comprehensive presentation of quantitative and qualitative results provides a robust foundation for evaluating the efficacy of AI-enabled pharmaceutical serialization within SAP QM, particularly in the context of FDA 21 CFR Part 11 compliance.

Discussion:

The present study elucidates the transformative impact of integrating artificial intelligence (AI) within SAP Quality Management (QM) systems on pharmaceutical serialization processes, particularly in achieving compliance with FDA 21 CFR Part 11. The findings indicate that AI integration not only enhances serialization accuracy but also facilitates real-time traceability and audit readiness, thereby shifting serialization from a traditionally reactive compliance activity to a proactive quality intelligence framework. This aligns with recent literature emphasizing the role of AI in automating regulatory compliance and improving data integrity in pharmaceutical manufacturing.

Comparatively, traditional serialization systems within SAP QM have predominantly relied on manual inspections, static validation rules, and post-process audit logging, which often result in delayed detection of anomalies and increased risk of non-compliance. The AI-enabled approach demonstrated in this study offers dynamic, real-time compliance monitoring and automated validation, which corroborates findings from recent studies advocating for intelligent automation in pharmaceutical quality management. Notably, the synchronization of serialization logic across multiple SAP modules (QM, ATTP, EWM) enhances cross-functional governance, a feature less emphasized in prior research but critical for complex, multi-site pharmaceutical operations.

The practical implications of these results are multifaceted. For pharmaceutical manufacturers, embedding AI within SAP QM workflows can substantially reduce regulatory risks by improving serialization accuracy and ensuring comprehensive traceability, which is essential for compliance with global regulations such as the Drug Supply Chain Security Act (DSCSA) and the European Union Falsified Medicines Directive (EU FMD). SAP consultants are prompted to develop AI-integrated configuration frameworks and mentoring resources to facilitate effective

implementation, addressing a current gap in clean-core documentation and training materials. Regulatory teams benefit from automated audit trails and electronic signature validations, which streamline inspection readiness and reduce manual documentation burdens, thereby enhancing operational efficiency. Furthermore, this AI-driven approach supports broader digital transformation initiatives by promoting intelligent automation and modular extensibility within GxP-compliant environments. Despite these promising outcomes, several limitations warrant consideration. The study was conducted within a controlled sandbox environment, which may not fully capture the complexities of live production systems, including multi-vendor serialization scenarios, network latency, and diverse user behaviors that could influence AI performance and compliance outcomes. Additionally, the AI models were trained on simulated datasets, potentially limiting their generalizability to rare or edge-case serialization failures encountered in heterogeneous pharmaceutical settings. The scope of validation was constrained, as comprehensive regulatory validation protocols such as Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) were not fully implemented, highlighting the need for cross-functional collaboration in future studies. The limited sample size of expert feedback, primarily from SAP consultants and QA leads, suggests that incorporating perspectives from auditors, IT security, and regulatory affairs could enrich the understanding of AI-enabled serialization. Lastly, the identified deficiency in mentoring resources for junior consultants may impede widespread adoption and consistent application of AI-enhanced serialization workflows.

Future research should prioritize live deployments of AI-enabled serialization within regulated SAP S/4HANA environments to evaluate performance under real-world FDA inspection conditions, including multi-site and multi-vendor complexities. Developing standardized validation protocols tailored for AI models embedded in SAP QM and ATTP is essential to ensure full compliance with FDA 21 CFR Part 11 and GxP standards. Cross-industry benchmarking across pharmaceutical, medical device, and biotechnology sectors could uncover transferable AI governance strategies and compliance best practices. Additionally, creating comprehensive mentoring frameworks, including clean-core guides and onboarding materials, will support junior consultants in effectively managing AI-integrated serialization workflows. Finally, investigating ethical and regulatory audits of AI decision-making processes within serialization such as anomaly detection and label verification will be critical to ensuring transparency and trustworthiness in AI-driven pharmaceutical quality management.

Conclusion:

This research highlights the transformative impact of integrating artificial intelligence (AI) into SAP Quality Management (QM) systems for pharmaceutical serialization. AI-driven capabilities such as automated inspection lot management, anomaly detection, and electronic signature verification reduce serialization errors by 42% and enhance audit trail integrity and cross-module governance across SAP QM, ATTP, and EWM. This shift redefines serialization from a manual compliance task into a dynamic, scalable, and audit-ready process.

Theoretically, the study advances the understanding of embedding intelligent automation within ERP frameworks to meet stringent regulatory mandates like FDA 21 CFR Part 11. Practically, it offers a replicable model for pharmaceutical quality teams and SAP consultants to improve serialization accuracy, ensure data integrity, and foster a proactive compliance culture.

Broader industry implications include enhanced traceability, regulatory confidence, and supply chain resilience especially vital in high-volume, multi-site manufacturing. Future research should focus on developing AI algorithms for multilingual, multi-regulatory environments (e.g., FMD, DSCSA, ANVISA), modularizing AI services on SAP BTP, and establishing clean-core mentoring frameworks to ensure sustainable compliance and knowledge transfer.

Ultimately, AI integration within SAP QM elevates serialization from regulatory necessity to strategic enabler, driving operational excellence, risk mitigation, and public health assurance in an increasingly complex global pharmaceutical landscape.

References:

Atalan, A. (2025). The ChatGPT application on quality management: A comprehensive review. *Journal of Management Analytics*, 12(2), 229–259. https://doi.org/10.1080/23270012.2025.2334567.

Basinger, R. (2024). Electronic records; electronic signature and data integrity. In M. A. Mehta & A. S. Rathore (Eds.). *Good clinical practices in pharmaceuticals* , (1st ed., Chapter 11). CRC Press. https://doi.org/10.1201/9781003407010-11.

Berry, I. R., & Martin, R. P. ((Eds.). (Year)). *The pharmaceutical regulatory process.* Publisher.

Borchers, A. T., Hagie, F., Keen, C. L., & Gershwin, M. E. (2007). The history and contemporary challenges of the US Food and Drug Administration. *Clinical Therapeutics*, 29(1), 1–16. https://doi.org/10.1016/j.clinthera.2007.01.006.

Boudrez, F. (2007). Digital signatures and electronic records. *Archival Science*, 7(3), 179–193. https://doi.org/10.1007/s10502-007-9058-2.

Bunn, G. (2003). The internal audit program: A quality assessment. In C. Medina (Ed.). *Compliance handbook for pharmaceuticals, medical devices, and biologics*, (1st ed., pp. 431–459). CRC Press. https://doi.org/10.1201/9780203026960-17.

Gerard, J. S., & Ramachandran, V. (2025). Navigating regulatory complexities in biosimilar approvals and imports for autoimmune disorder management: A comparative analysis of FDA (US). *EMA (EU), and CDSCO (India) guidelines. Recent Advances in Drug Delivery and Formulation*, https://doi.org/10.2174/0126673878360952250715031025.

Gueorguiev, T. (2023). An approach to integrate artificial intelligence in ISO 9001-based quality management systems. *Procedia Computer Science*, 217, 1106–1112. https://doi.org/10.1016/j.procs.2022.12.143\.

Huseynov, K., Cakir, L. V., Al-Shareeda, S., Özdem, M., & Canberk, B. (2024). A data serialization-based framework for efficient IoT management. *In 2024 IEEE 10th World Forum on Internet of Things*, (WF-IoT) (pp. 1–6). IEEE. https://doi.org/10.1109/WF-IoT60794.2024.10811147.

Immidi, K., Chaudhari, K., & Mane, S. (2025). Design and implementation of an integrated quality management system using SAP QM. *International Journal of Engineering Research & Technology (IJERT)*, 14(10). https://www.ijert.org/design-and-implementation-of-an-integrated-quality-management-system-using-sap-qm.

Jampani, S., Mokkapati, C., Chinta, U., Singh, N., Goel, O., & Chhapola, A. (2022). Application of AI in SAP implementation projects. *International Journal of Applied Mathematics & Statistical Sciences (IJAMSS)*, 11(2), 45–60. https://www.researchgate.net/publication/390200538.

Martin, K. C., & Perez, A. R. (2008). GAMP 5 quality risk management approach. Reprinted from The Official Magazine of ISPE, 28(3). International Society for Pharmaceutical Engineering (ISPE). *Retrieved from*, https://www.akility.com/wp-content/uploads/2024/04/ISPE-GAMP-5-Quality-Risk-Management-Approach.pdf.

Nair, S. (2025). Explainable AI in GxP validation: Balancing automation, traceability, and regulatory trust in the pharmaceutical industry. *Clinical Medicine and Health Research Journal*, 5(5), 1430–1442. https://doi.org/10.18535/cmhrj.v5i05.509.

Ojha, R., & Jaiswal, C. M. (2023). SAP S/4HANA asset management: Configure, equip, and manage your enterprise. *Apress*, https://doi.org/10.1007/978-1-4842-9870-1.

Parmaksiz, K., Pisani, E., & Kok, M. O. (2020). What makes a national pharmaceutical track and trace system succeed? Lessons from Turkey. *Global Health: Science and Practice*, 8(3), 431–441. https://doi.org/10.9745/GHSP-D-20-00084.

Rivers, M. (2021). Serialization and aggregation from a manufacturing perspective. *BioPharm International*, https://www.biopharminternational.com/view/serialization-and-aggregation-from-a-manufacturing-perspective.

Venable, J., Pries-Heje, J., & Baskerville, R. (2012). A comprehensive framework for evaluation in design science research. In K. Peffers, M. Rothenberger, & B. Kuechler (Eds.), Design science research in information systems. *Advances in theory and practice*, (pp. 423–438). Springer. https://doi.org/10.1007/978-3-642-29863-9_31.